Clazosentan
As of the edition of 20 October 2026, Clazosentan is a small molecule: marketed, first approved in 2022 (JP); acts on EDNRA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Pivlaz I.V.
- First approved
- 20 January 2022 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Idorsia Pharmaceuticals
- Registered trials
- 7, 1 stopped early
- Disease areas
- Heart and blood vessels; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EDNRA | Endothelin-1 receptor | P25101 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Idorsia Pharmaceuticals | Applicant and Lead sponsor of trials | 2005 to now |